Publications by authors named "Marie Kromplewski"
Article Synopsis
- The study aimed to assess the safety, specifically the toxicity profile and maximum-tolerated dose (MTD), of the drug cediranib in children and adolescents with solid tumors.
- Sixteen patients were treated, with dose adjustments based on observed toxicities; the MTD was established at 12 mg/m²/day.
- Positive responses were noted in certain tumor types, leading to the conclusion that 12 mg/m²/day is the recommended dose for future studies in this population.
Pharmacokinetics of orally administered ABT-751 in children with neuroblastoma and other solid tumors.
Cancer Chemother Pharmacol
September 2010
Purpose: To describe the pharmacokinetics of orally administered ABT-751 and its conjugated metabolites in children with neuroblastoma and other solid tumors and to relate pharmacokinetic parameters to toxicity and therapeutic outcomes.
Methods: Patients (median age, 11 years) with neuroblastoma (n = 37) or other solid tumors (n = 25) had pharmacokinetic sampling after the first dose of ABT-751 (75-250 mg/m(2)/day) on a 7-day or 21-day schedule. ABT-751 and its glucuronide and sulfate metabolites were quantified with an HPLC/MS/MS assay.
Purpose: To determine the toxicity profile, dose-limiting toxicities (DLT), and maximum tolerated dose (MTD) of ABT-751 administered orally once daily for 21 days, repeated every 28 days in a pediatric population.
Experimental Design: Patients who were < or = 18 years with relapsed or refractory solid tumors and who were able to swallow capsules were eligible. The starting dose was 75 mg/m(2)/d (n = 3) and was escalated to 100 (n = 6), 130 (n = 5), and 165 (n = 3) mg/m(2)/d in cohorts of three to six patients.
Purpose: To determine the toxicity profile, dose-limiting toxicities, and maximum tolerated dose of ABT-751 administered orally once daily for 7 days, repeated every 21 days.
Experimental Design: Patients who were View Article and Find Full Text PDF